Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer

doi:10.3748/wjg.v26.i19.2427

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7098)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

388

WORD

157

HTML

3762

Figures (1-3)

359

Tables (1-5)

330

Sum=4996

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

729

Download

1373

Sum=2102

May 21, 2020 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. May 21, 2020; 26(19): 2427-2439
Published online May 21, 2020. doi: 10.3748/wjg.v26.i19.2427

Table 1 Patient characteristics and P value of univariate analysis

Characteristics	Total	Non-pCR	pCR	P value
Number of patients	208	181	27
Sex
Male	161	138	23	0.3
Female	47	43	4	0.3
Age	59 (50-64)	59 (50-64)	59 (51-63)	0.631
BMI	22 ± 2.9	22 ± 2.9	22 ± 3.4	0.226
Location
Esophago-gastric junction	61	53	8	0.1
Upper third	25	20	5
Middle third	43	42	1
Lower third	79	66	13
Tumor differentiation
Well differentiated	8	5	3	0.025
Moderately differentiated	56	46	10
Moderately-poorly differentiated	28	22	6
Poorly differentiated	94	87	7
Signet ring cell	22	21	1
Clinical T staging
T3	103	88	15	0.725
T4a	84	75	9
T4b	21	18	3
Clinical N staging
N0	4	4	0	0.435
N+	204	177	27	0.435
Regimen
mFLOT	122	102	20	0.217
SOX/FOLFOX/XELOX	75	69	6
other	11	10	1
Cycles	4 (4-5)	4 (4-5)	4 (4-4)	0.766
WBC, 10⁹/L)	6.47 ± 1.89	6.51 ± 1.93	5.80 ± 1.48	0.061
RBC, 10¹²/L	4.39 (3.84-4.72)	4.42 (3.9-4.73)	4.23 (3.69-4.55)	0.263
NEU, 10⁹/L	3.76 (2.82-4.9)	3.86 (2.89-4.97)	3.05 (2.61-3.58)	0.589
NEUR	0.61 ± 0.1	0.62 ± 0.11	0.57 ± 0.07	0.2
LYM, 10⁹/L	1.62 (1.26-2.07)	1.6 (1.22-2.08)	1.71 (1.42-2.07)	0.107
LYMR	0.26 (0.2-0.33)	0.24 (0.2-0.33)	0.32 (0.28-0.35)	0.001
MONO, 10⁹/L	0.5 (0.4-0.64)	0.51 (0.41-0.64)	0.44 (0.31-0.57)	0.017
MONOR	0.08 (0.07-0.1)	0.08 (0.07-0.1)	0.08 (0.06-0.09)	0.211
EOS, 10⁹/L	0.13 (0.08-0.21)	0.13 (0.08-0.21)	0.15 (0.08-0.22)	0.428
EOSR	0.02 (0.01-0.03)	0.02 (0.01-0.03)	0.03 (0.02-0.05)	0.071
BASO, 10⁹/L	0.03 (0.02-0.04)	0.03 (0.02-0.04)	0.04 (0.01-0.05)	0.513
BASOR	0.01 (0-0.01)	0.01 (0-0.01)	0.01 (0-0.01)	0.299
HGB, g/L	123 (97.18-137)	123 (99-137)	118 (81-134.1)	0.373
PLT, 10⁹/L	262.5 (211.7-330)	262 (212.8-328)	263 (197-358)	0.809
UA, μmol/L	348.7 (274-420.8)	342 (263.9-413.3)	407.3 (341-481.6)	0.003
Cr, μmol/L	78.4 (66.4-89.1)	77.3 (64.92-89)	81.09 (75.5-89.5)	0.176
ALT, U/L	13.8 (9.86-18.98)	13.79 (9.91-19)	14 (9.69-18)	0.958
AST, U/L	18.2 (14.8-22.1)	18.5 (14.84-22.11)	17.02 (13.39-22.1)	0.37
r-GT, U/L	18.8 (14.8-30.4)	18.8 (14.61-30.28)	18.51 (15-34.71)	0.672
TP, g/L	68.2 ± 6.53	67.86 ± 6.52	70.37 ± 6.3	0.89
Alb, g/L	39.81 ± 4.39	39.59 ± 4.47	41.23 ± 3.53	0.1
AKP, U/L	84.6 (68.1-100.5)	85.61 (70-101.55)	77.44 (58.97-91)	0.156
PA, g/L	0.2 ± 0.06	0.2 ± 0.06	0.21 ± 0.05	0.59
TBIL, μmol/L	11 (8.67-14.45)	11.12 (8.85-14.39)	10.48 (6.92-16.24)	0.421
DBIL, μmol/L	2.21 (1.68-3.08)	2.25 (1.68-3.08)	2.05 (1.46-2.99)	0.29
LD, U/L	167 (147.9-194.7)	167 (147.8-191.4)	168 (149.5-197.3)	0.548
CH, mmol/L	4.79 ± 1.1	4.73 ± 1.1	5.15 ± 1	0.26
TG, mmol/L	1.06 (0.83-1.38)	1.03 (0.83-1.38)	1.15 (0.81-1.47)	0.588
HDL, mmol/L	1.15 (0.95-1.32)	1.14 (0.95-1.3)	1.24 (1.06-1.41)	0.088
LDL, mmol/L	3.06 (2.52-3.50)	2.95 (2.47-3.51)	3.25 (2.92-3.50)	0.08
CRP, mg/L	2.36 (0.91-9.09)	2.37 (0.91-9.78)	2.17 (0.83-5.85)	0.593
CA125, U/mL	14.95 (9.4-23.55)	15.1 (9.5-24.4)	12.5 (7.6-20)	0.375
CEA, ng/mL	2.8 (1.43-5.92)	2.51 (1.38-4.88)	8.04 (2.36-26.2)	0.002
CA199, U/mL	9.71 (2.86-40.35)	8.87 (2.4-47.64)	15.32 (4.46-34.15)	0.303
CA-153, U/mL	7.5 (5.38-11)	7.4 (5.3-10.8)	8.3 (6.2-11.9)	0.289
AFP, ng/mL	2.7 (1.97-4.28)	2.67 (1.94-4.19)	2.78 (2.06-10.96)	0.551
Blood type
Type O	75	72	3	0.005
Type A	61	46	15
Type B	50	43	7
Type AB	22	20	2

WBC: White blood cell; RBC: Red blood cell; NEU: Neutrophil cell; NEUR: Neutrophil cell ratio; LYM: Lymphocyte; LYMR: Lymphocyte ratio; MONO: Monocyte; MONOR: Monocyte ratio; EOS: Eosinophil; EOSR: Eosinophil ratio; BASO: Basophil; BASOR: Basophil ratio; HGB: Hemoglobin; PLT: Platelets; UA: Uric acid; Cr: Creatinine; ALT: Alanine transaminase; AST: Aspartate transaminase; r-GT: Gamma-glutamyl transpeptidase; TP: Total protein; Alb: Albumin; AKP: Alkaline phosphatase; PA: Prealbumin; TBIL: Total bilirubin; DBIL: Direct bilirubin; LD: Lactate dehydrogenase; CH: Cholesterol; TG: Triglyceride; HDL: High density lipoprotein; LDL: Low density lipoprotein; CRP: C-reactive protein; CA125: Carbohydrate antigen 125; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; CA-153: Carbohydrate antigen 153; AFP: Alpha fetoprotein; BMI: Body mass index.

Citation: Chen YH, Xiao J, Chen XJ, Wang HS, Liu D, Xiang J, Peng JS. Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. World J Gastroenterol 2020; 26(19): 2427-2439
URL: https://www.wjgnet.com/1007-9327/full/v26/i19/2427.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i19.2427